Acidic fibroblast growth factor (aFGF) and basic fibroblast growth factor (bFGF) were initially characterized and purified on the basis of their mitogenic activities toward fibroblasts (7, 8) . Subsequent studies have shown that FGFs stimulate a remarkably diverse group of biological responses (reviewed in references 3, 10, and 35), including proliferation of endothelial cells (9, 18) , neurite outgrowth (24, 36, 37) , survival of lesioned cholinergic neurons in vivo (1) , and early steps of embryonic development (15, 16, 33) .
In recent years, the complexity of the FGF system has become apparent with the discovery of at least seven genes that encode factors in the FGF family. The factors that have been identified include aFGF, bFGF, the product of the int-2 oncogene (23) , the product of the hst oncogene (Kaposi sarcoma FGF) (4, 34) , , , and keratinocyte growth factor (KGF) (29) . There are also multiple genes that encode FGF receptors (5, 11, 12, 14, 17, 22, 25, 26) . We have referred to the known FGF receptors as FGF receptors 1, 2, and 3 (FGFR 1 to 3).
The first identification of a full-length cDNA for an FGF receptor was based on experiments in which a functional FGF receptor was purified from chicken embryos (17) . The cDNA encoding this purified protein was closely related to a previously published partial cDNA (30) of a fms-like gene (fig) that had been isolated on the basis of tyrosine kinase sequence homologies. It is now apparent that the FGF receptor and its related genes form a subclass of tyrosine kinase receptors that are different from the Fms/plateletderived growth factor receptor group and other tyrosine kinase receptors. We refer to this first FGF receptor as FGFR 1. This gene is identical to the flg (human) (30) and Cekl (chicken) genes (26) . The chicken cDNA clones that were isolated for FGFR 1 were predicted to encode a protein * Corresponding author.
that has three immunoglobulin (Ig)-like domains in the extracellular region, a single membrane-spanning segment, and a tyrosine kinase domain in the cytoplasmic region ( Fig.  1 shows a schematic diagram of the receptor protein). In subsequent studies, human and mouse cDNAs encoding three-Ig-domain forms of FGFR 1 were isolated (5, 28) . However, additional cDNA clones were found to encode FGFR 1 proteins containing only two Ig domains (13, 28) (Fig. 1 ). These two domains corresponded to the second and third Ig domains of the three-Ig-domain form of the receptor. Functional characterization of the cloned FGFR 1 proteins showed that both the three-and two-Ig-domain forms of the receptor can bind and become activated by either aFGF or bFGF (5, 13) . These experiments demonstrated that (i) a single receptor protein can bind different members of the FGF family and (ii) the first Ig domain of the FGF receptor is not essential for binding aFGF and bFGF.
In addition to two-and three-Ig-domain forms of FGFR 1 that span the membrane, we isolated a cDNA encoding a secreted form of the receptor (13) (Fig. 1) sequence for the second half of the third Ig domain. Therefore, there are three possible coding sequences for this region of the receptor molecule.
Recent studies have shown that the product of the FGFR 2 gene (variously called bek [5] , Cek3 [25] , K-sam [11] , TK14 [12] , and KGF receptor [22] ) also is capable of binding both aFGF and bFGF (5, 22) . A naturally occurring variant of FGFR 2 (the KGF receptor [22] ) that lacks some sequence in the extracellular region is activated by KGF. Overall, FGFR 2 is similar in structure and sequence to FGFR 1. As is the case for FGFR 1, both three-and two-Ig-domain forms of the FGFR 2 protein have been identified. We have determined the structural organization of the human FGFR 2 gene in the region encoding the third Ig domain. These studies indicate that the FGFR 2 gene is organized in a fashion nearly identical to that of the FGFR 1 gene. In both cases, multiple forms that differ in their third Ig domain are expressed. The expression of each unique form can be attributed to either alternative splicing or selective use of polyadenylation signals. Using PCR, we amplified, subcloned, and sequenced 13 overlapping human genomic fragments, each of which contained at least one but not more than two introns. The primers were based on human FGFR 1 cDNA sequences (13) . Listed below are the primer combinations, starting at the 5' end of the coding region, that were used to amplify the 13 overlapping genomic fragments (fragment numbers are underlined). For each primer pair, the 5' primer is listed first, followed by the 3' primer. Indicated in parentheses is the exon number from which the primers were derived (Fig. 2) . In some cases, primers were derived from intronic sequences. In these cases, the location of the intron from which the primer was derived is indicated. The primer pairs are as follows: 5'-GA(T/C)GACGTGCAG(A/T)(G/C)CATC AACTGGGTGCGTGATGG-3' (exon 1) and 5'-CATCTTT TCTGGGGATGTCCAATATGGA-3' (exon 3); 5'-CTCTTC To characterize the region of the FGFR 2 gene encoding Ig domain III, we used PCR to generate three overlapping genomic fragments. Primers were designed on the basis of the published sequences of FGFR 2 cDNAs (5, 11). The primer combinations used to generate these three fragments were as follows: 5'-GAAAAGAACGGCAGTAAAT-3' (exon 5) and 5'-CACTTCTGCATTGGAACTAT-3' (exon 6); 5'-GACCATAGACAATGCTAAGA-3' (derived from sequence at the 3' end of the intron directly preceding exon 6) and 5'-GAGAACCTCAATCTCTTTGT-3' (exon 7); and 5'-ATCATTCCTGTGTCGTCTA-3' (derived from sequence at the 3' end of the intron directly preceding exon 7) and 5'-TCATAGTCTGGGGAAGCTGTAATCT-3' (exon 8).
MATERIALS
Following the final extension of PCR reactions, 1 U of Klenow enzyme was added to each reaction mix, and extension was allowed to continue for 30 min at room temperature. Reaction products were then subcloned into the SmaI site of Bluescript KS (Stratagene), and subclones were sequenced (32) to determine the precise locations of intronic sequences.
Isolation of human RNA. Polyadenylated human RNA was isolated from cells by using a Fast Track kit (Invitrogen) as specified by the manufacturer. Total cellular RNA was isolated from cells by using guanidinium isothiocyanate as previously described (6) .
Probes used for RNase protection assays. DNA probes specific for each of the three alternative coding sequences for the second half of Ig domain III (Illa, ITlb, and IMIc) were subcloned into Bluescript KS. The secreted form-specific probe, Illa, represents a 410-bp AccI-SalI fragment of the published secreted-form cDNA (13) (13) were used to amplify regions of the gene, using human genomic DNA as a template for PCR (31) . Using this approach, we amplified, subcloned, and sequenced 13 overlapping genomic fragments, each of which contained at least one but not more than two introns. The overlapping fragments covered the region extending from the amino-terminal half of Ig domain I to the 3' nontranslated region associated with the membrane-spanning receptor forms (Fig. 2) . Figure  2 indicates the locations and sizes of intronic sequences in the FGFR 1 coding region. We were unable to amplify any fragments with use of a primer derived from the 5' nontranslated region or signal peptide sequence and a primer derived from Ig domain I, indicating that there may be a large intron(s) located in this region. For this reason, we started our numbering of exons with number 2 (Fig. 2) . Figure 3 shows the nucleotide sequence of each intron-exon boundary. In general, the observed splice junction sequences were similar to published consensus sequences (2) . However, in some cases the junction sequences differed from the consensus sequences (Fig. 3) .
Genomic sequences involved in the generation of a secreted form of FGFR 1. Previously we have shown that at least two forms of FGFR 1 that differ in the third Ig domain are expressed (13) . One of these forms represents a secreted extracellular domain that lacks transmembrane sequences, whereas the other form represents a membrane-spanning form of the receptor. The coding region of the secreted FGFR 1 form diverges completely from the sequence of the membrane-spanning forms at a position approximately halfway through Ig domain III (Fig. 1) . Also, cDNAs encoding the secreted form of receptor contain approximately 0.95 kb of 3' nontranslated sequence which is distinct from the 3' nontranslated sequences of cDNAs encoding membranespanning receptors. When a primer derived from the aminoterminal half of Ig domain III (labeled 5' in Fig. 2 ) and a primer derived from the carboxyl-terminal half of the membrane-spanning form of Ig domain III (labeled 3') were used to amplify genomic DNA, a single 2.6-kb fragment was I. amplified. In this genomic fragment, sequences encoding the unique region of the secreted form of receptor are continuous with sequences encoding the amino-terminal half of Ig domain III and are followed by a stop codon and a 3' nontranslated sequence previously found in the cDNA sequence of the secreted receptor (Fig. 2) . Although the published sequences of the secreted form cDNAs do not contain a polyadenylation signal (27) , a consensus polyadenylation signal (AATAAA) is found in the genomic sequence only 16 nucleotides downstream from the 3' end of the published cDNA sequence for the secreted form (Fig. 6) (Fig. 2 and 3 show the exon boundaries).
We were unable to amplify any cDNA fragments when we used a primer (5' primer) derived from the new exon and a primer (3' primer) derived from the cytoplasmic coding region sequence. However, by analogy with the FGFR 2 gene, it is likely that this newly discovered exon is part of mRNA transcripts encoding a membrane-spanning form of the receptor (see Discussion). Thus, there are at least three alternative exons that can code for the carboxy-terminal half of Ig domain III (labeled IlIa, ITlb, and IIlc in Fig. 2 Methods for a description of the probes). Some of the cell lines tested (astrocytoma, neuroblastoma, and adrenal cortex) simultaneously expressed transcripts for each of the three different receptor forms (Fig. 4) . Also, one cell line, foreskin fibroblasts, expressed only the IIIc exon. In summary, with the exception of foreskin fibroblasts cells, the patterns of expression of the three alternative exons are highly similar. It should be noted, however, that the levels of the different mRNA transcripts probably differ widely. This conclusion is based on the facts that the protection assay shown in Fig. 4A (IIIa; secreted form-specific probe) was exposed to film for 10 days, the protection assay shown in Fig. 4B (IlIb probe) was exposed for 2 days, and the protection assay shown in Fig. 4C (IlIc probe) was exposed for only 5 h.
Comparison of the three exons encoding the second half of Ig domain III. Figure 5A shows an alignment of the IIIa, IlIb, and IlIc amino acid sequences of FGFR 1. Interestingly, the two exons that appear to be part of membranespanning forms of FGFR 1 (IIlb and Ilc) are identical in 22 of 49 amino acids (45%). In contrast, the amino acid sequence ofIlla (secreted form) shows no apparent homology to the sequence of either IIlb or Ilc.
Recently, cDNAs encoding transmembrane forms of FGFR 2 that differ in the second half of Ig domain III have been reported. Two of these cDNAs (K-sam [11] and the KGF receptor [22] ) encode a sequence that is highly similar to the IIIb sequence of FGFR 1. This sequence is shown in Fig. SB and is labeled FGFR 2 TIlb. Since the FGFR 2 IIIb sequence is part of a membrane-spanning receptor, it seems highly likely that the FGFR 1 Ilb exon that we have discovered also is part of a transmembrane receptor form. The other two known FGFR 2 cDNAs (bek [5] and TK14 [12] ) encode a sequence highly similar to the Ilc sequence of [11] or KGF receptor [22] ), while others contain sequences representing the IlIc form of FGFR 2 (bek [5] or TK14 [12] 
